$0.93
1.09% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US23283X2062
Symbol
CTSO

CytoSorbents Corporation Stock price

$0.93
-0.11 10.58% 1M
+0.03 3.33% 6M
-0.18 16.22% YTD
-0.30 24.39% 1Y
-4.09 81.47% 3Y
-3.10 76.92% 5Y
-4.45 82.70% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.01 1.09%
ISIN
US23283X2062
Symbol
CTSO
Sector

Key metrics

Market capitalization $50.85m
Enterprise Value $71.97m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.91
P/S ratio (TTM) P/S ratio 1.35
P/B ratio (TTM) P/B ratio 3.90
Revenue growth (TTM) Revenue growth 1.80%
Revenue (TTM) Revenue $37.74m
EBIT (operating result TTM) EBIT $-21.59m
Free Cash Flow (TTM) Free Cash Flow $-18.80m
Cash position $5.69m
EPS (TTM) EPS $-0.36
P/E forward negative
P/S forward 1.31
EV/Sales forward 1.86
Short interest 2.56%
Show more

Is CytoSorbents Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

CytoSorbents Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a CytoSorbents Corporation forecast:

1x Buy
50%
1x Hold
50%

Analyst Opinions

2 Analysts have issued a CytoSorbents Corporation forecast:

Buy
50%
Hold
50%

Financial data from CytoSorbents Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
38 38
2% 2%
100%
- Direct Costs 14 14
1% 1%
37%
24 24
4% 4%
63%
- Selling and Administrative Expenses 33 33
1% 1%
89%
- Research and Development Expense 9.72 9.72
35% 35%
26%
-19 -19
25% 25%
-52%
- Depreciation and Amortization 2.11 2.11
40% 40%
6%
EBIT (Operating Income) EBIT -22 -22
21% 21%
-57%
Net Profit -19 -19
20% 20%
-49%

In millions USD.

Don't miss a Thing! We will send you all news about CytoSorbents Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CytoSorbents Corporation Stock News

Neutral
GlobeNewsWire
15 days ago
PRINCETON, N.J. and HYDERABAD, India, Nov. 11, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit (ICU) and during cardiac surgery through blood purification, and Converge Biotech, a prominent healthcare company with a strong critical care and infectious disease focus in India, are pleased to anno...
Neutral
Seeking Alpha
17 days ago
Cytosorbents Corporation (NASDAQ:CTSO ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Adanna Alexander - IR Phillip Chan - CEO & Director Peter Mariani - CFO Conference Call Participants Tom Kerr - Zacks Small-Cap Research Operator Thank you for standing by. My name is Catherine, and I will be your conference operator today.
Neutral
GlobeNewsWire
about 2 months ago
CytoSorbents files for FDA De Novo marketing approval of DrugSorb-ATR to reduce the severity of CABG-related bleeding due to the blood thinner ticagrelor
More CytoSorbents Corporation News

Company Profile

CytoSorbents Corp. engages in the critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio include CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.

Head office United States
CEO Phillip Chan
Employees 186
Founded 2002
Website cytosorbents.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today